194 related articles for article (PubMed ID: 33576871)
1. Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.
Yang P; Wang K; Zhang C; Wang Z; Liu Q; Wang J; Jiang T; Shan X
Cancer Immunol Immunother; 2021 Sep; 70(9):2589-2600. PubMed ID: 33576871
[TBL] [Abstract][Full Text] [Related]
2. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
3. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
4. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
5. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
6. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.
Chen R; Wang X; Dai Z; Wang Z; Wu W; Hu Z; Zhang X; Liu Z; Zhang H; Cheng Q
Front Immunol; 2021; 12():713757. PubMed ID: 34712225
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
Liu H; Weng J
Gene; 2022 May; 822():146325. PubMed ID: 35183683
[TBL] [Abstract][Full Text] [Related]
9. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
[TBL] [Abstract][Full Text] [Related]
10. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
11. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
12. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
[TBL] [Abstract][Full Text] [Related]
13. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
14. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
16. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas.
Liu X; Li Y; Sun Z; Li S; Wang K; Fan X; Liu Y; Wang L; Wang Y; Jiang T
Cancer Med; 2018 Sep; 7(9):4273-4283. PubMed ID: 30117304
[TBL] [Abstract][Full Text] [Related]
19. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
20. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.
Wang ZL; Wang Z; Li GZ; Wang QW; Bao ZS; Zhang CB; Jiang T
Front Immunol; 2019; 10():1756. PubMed ID: 31428092
[No Abstract] [Full Text] [Related]
[Next] [New Search]
